1. Home
  2. MLKN vs NTLA Comparison

MLKN vs NTLA Comparison

Compare MLKN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLKN
  • NTLA
  • Stock Information
  • Founded
  • MLKN 1905
  • NTLA 2014
  • Country
  • MLKN United States
  • NTLA United States
  • Employees
  • MLKN N/A
  • NTLA N/A
  • Industry
  • MLKN Office Equipment/Supplies/Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • MLKN Consumer Discretionary
  • NTLA Health Care
  • Exchange
  • MLKN Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • MLKN 1.2B
  • NTLA 1.2B
  • IPO Year
  • MLKN N/A
  • NTLA 2016
  • Fundamental
  • Price
  • MLKN $21.47
  • NTLA $10.90
  • Analyst Decision
  • MLKN
  • NTLA Buy
  • Analyst Count
  • MLKN 0
  • NTLA 20
  • Target Price
  • MLKN N/A
  • NTLA $32.30
  • AVG Volume (30 Days)
  • MLKN 393.5K
  • NTLA 5.0M
  • Earning Date
  • MLKN 09-18-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • MLKN 3.45%
  • NTLA N/A
  • EPS Growth
  • MLKN N/A
  • NTLA N/A
  • EPS
  • MLKN N/A
  • NTLA N/A
  • Revenue
  • MLKN $3,669,900,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • MLKN $4.74
  • NTLA N/A
  • Revenue Next Year
  • MLKN $3.64
  • NTLA N/A
  • P/E Ratio
  • MLKN N/A
  • NTLA N/A
  • Revenue Growth
  • MLKN 1.14
  • NTLA 14.99
  • 52 Week Low
  • MLKN $15.25
  • NTLA $5.90
  • 52 Week High
  • MLKN $30.56
  • NTLA $24.16
  • Technical
  • Relative Strength Index (RSI)
  • MLKN 64.77
  • NTLA 45.06
  • Support Level
  • MLKN $19.62
  • NTLA $10.57
  • Resistance Level
  • MLKN $21.81
  • NTLA $11.51
  • Average True Range (ATR)
  • MLKN 0.72
  • NTLA 0.69
  • MACD
  • MLKN 0.18
  • NTLA -0.26
  • Stochastic Oscillator
  • MLKN 90.16
  • NTLA 10.44

About MLKN MillerKnoll Inc.

MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: